SEC Form 4 · accession 0001415889-18-000014
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glenn Baity
Officer — EVP AND GC
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 6:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 2, 2018 | M | 74,321 | $2.18 | A | 144,434 | D | |
| Common StockF3 | Jan 2, 2018 | S | 74,321 | $30.1414 | D | 70,113 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $2.18 | Jan 2, 2018 | M | 74,321 | D | — | Mar 22, 2022 | Common Stock | 74,321 | 0 | D |
Explanation of responses
- F1Includes 457 shares acquired on November 15, 2017 by Mr. Baity under the ACADIA Pharmaceuticals Employee Stock Purchase Plan.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017 and amended in November 2017.
- F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.335 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- F425% of the shares subject to the Stock Option vested and became exercisable on March 23, 2013. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.